Physician profile
Karsten Johnson
NPI 1154700839
$10,591.00
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,642 · 2020: $6,949.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,296.78 | 2020 | |
| Abbvie INC. | $1,714.08 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,505.42 | 2019-2020 | |
| Celgene Corporation | $606.25 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $289.27 | 2019-2020 | |
| Lilly USA, LLC | $234.57 | 2019-2020 | |
| Janssen Biotech, INC. | $163.84 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $140.64 | 2019-2020 | |
| Ucb, INC. | $128.30 | 2019-2020 | |
| Almirall LLC | $118.94 | 2019 | |
| Genzyme Corporation | $104.17 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| Genentech USA, INC. | $36.11 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $32.34 | 2019 | |
| Dermira, INC. | $32.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.93 | 2019 | |
| Galderma Laboratories, L.P. | $27.73 | 2019 | |
| Leo Pharma INC. | $17.17 | 2019 | |
| Csl Behring | $15.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karsten Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.